Discovery of dabrafenib: A selective inhibitor of Raf Kinases with antitumor activity against B-Raf-driven tumors

ACS Medicinal Chemistry Letters

Volumn 4, Issue 3, 2013, Pages 358-362

  Rheault, Tara R ^a   Stellwagen, John C ^a   Adjabeng, George M ^a   Hornberger, Keith R ^a   Petrov, Kimberly G ^a   Waterson, Alex G ^a   Dickerson, Scott H ^a   Mook, Robert A ^a   Laquerre, Sylvie G ^a   King, Alastair J ^a   Rossanese, Olivia W ^a   Arnone, Marc R ^a   Smitheman, Kimberly N ^a   Kane Carson, Laurie S ^a   Han, Chao ^a   Moorthy, Ganesh S ^a   Moss, Katherine G ^a   Uehling, David E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

B Raf; dabrafenib; GSK2118436; MAP kinase; melanoma

Indexed keywords

B RAF KINASE; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; COLORECTAL CARCINOMA; DEALKYLATION; DRUG CLEARANCE; ENZYME ACTIVITY; GENE MUTATION; IC 50; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; MELANOMA; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHARMACOPHORE; PLASMA CLEARANCE; PRIORITY JOURNAL;

EID: 84875186930     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4000063     Document Type: Article

References (13)

1. Davies, H.; Bignell, G.; Cox, C.; Stevens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G.; Bigner, D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J.; Leung, S.; Yuen, S.; Weber, B.; Seigler, H.; Darrow, T.; Paterson, H.; Marais, R.; Marshall, C.; Wooster, R.; Stratton, M.; Futreal, P. Mutations of the BRAF gene in human cancer Nature 2002, 417, 949-954 (Pubitemid 34716871)
2. Singer, G.; Oldt, R.; Cohen, Y.; Wang, B.; Sidransky, D.; Kurman, R.; Shih, Ie. M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J. Natl. Cancer Inst. 2003, 95, 484-486 (Pubitemid 36432423)
3. Cohen, Y.; Xing, M.; Mambo, E.; Guo, Z.; Wu, G.; Trink, B.; Beller, U.; Westra, W. H.; Ladenson, P. W.; Sidransky, D. BRAF mutation in papillary thyroid carcinoma J. Natl. Cancer Inst. 2003, 95, 625-627 (Pubitemid 36553510)
4. Yuen, S.; Davies, H.; Chan, T.; Ho, J.; Bignell, G.; Cox, C.; Stephens, P.; Edkins, S.; Tsui, W.; Chan, A.; Futreal, P.; Stratton, M.; Wooster, R.; Leung, S. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia Cancer Res. 2002, 62, 6451-6455 (Pubitemid 35364105)
5. Wan, P.; Garnett, M.; Roe, S.; Lee, S.; Niculescu-Duvaz, D.; Good, V.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of Action of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF Cell 2004, 116, 855-867 (Pubitemid 38410730)
6. Tsai, J.; Lee, J.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N.; Sproesser, K.; Li, L.; Smalley, K.; Fong, D.; Zhu, Y.-L.; Marimuthu, A.; Nguyen, H.; Lam, W.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S.-H.; Schlessinger, J.; Zhang, K.; West, B.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P.; Hirth, P.; Artis, D.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3041-3046 (Pubitemid 351723664)
7. Chapman, P.; Hauschild, A.; Robert, C.; Haanen, J.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S.; Sosman, J.; Kirkwood, J.; Eggermont, A.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R.; Flaherty, K. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 2011, 364, 2507-2516
8. V600E Inhibitors Containing an Arylsulfonamide Headgroup Bioorg. Med. Chem. Lett. 2011, 21, 4436-4440
9. For a thorough biological characterization of dabrafenib, see: King, A.; Arnone, M.; Bleam, M.; Moss, K.; Yang, J.; Fisher, K.; Smitheman, K.; Erhardt, J.; Hughes-Earle, A.; Kane-Carson, L.; Sinnamon, R.; Qi, H.; Rheault, T.; Uehling, D.; Laquerre, S. Novel Selective BRAF Inhibitor (GSK2118436; dabrafenib) with Demonstration of Increased Efficacy and Reduced Skin Lesions by Combining BRAF and MEK Inhibitors. Manuscript in preparation.
10. Gellibert, F.; de Gouville, A.-C.; Woolven, J.; Mathews, N.; Nguyen, V.-L.; Bertho-Ruault, C.; Patikis, A.; Grygielko, E.; Laping, N.; Huet, S. Discovery of 4-{4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro- 2H-pyran-4-yl)benzamide (GW788388): A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor Inhibitor J. Med. Chem. 2006, 49, 2210-2221
11. Hauschild, A.; Grob, J.; Demidov, L.; Jouary, T.; Gutzmer, R.; Millward, M.; Rutkowski, P.; Blank, C.; Miller, W.; Kaempgen, E.; Martín-Algarra, S.; Karaszewska, B.; Mauch, C.; Chiarion-Sileni, V.; Martin, A.; Swann, S.; Haney, P.; Mirakhur, B.; Guckert, M.; Goodman, V.; Chapman, P. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial Lancet 2012, 380, 358-365
12. Falchook, G.; Long, G.; Kurzrock, R.; Kim, K.; Arkenau, T.; Brown, M.; Hamid, O.; Infante, J.; Millward, M.; Pavlick, A.; O'Day, S.; Blackman, S.; Curtis, C.; Lebowitz, P.; Ma, B.; Ouellet, D.; Kefford, R. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Lancet 2012, 379, 1893-1901
13. Weber, J.; Flaherty, K.; Infante, J.; Falchook, G.; Kefford, R.; Daud, A.; Hamid, O.; Gonzalez, R.; Kudchadkar, R.; Lawrence, D.; Burris, H.; Long, G.; Algazi, A.; Lewis, K.; Kim, K.; Puzanov, I.; Sun, P.; Little, S.; Patel, K.; Sosman, J. Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma ASCO Meeting Abstracts 2012, 30, 8510